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CHAPTER I 
 
INTRODUCTION 
1.1 INTRODUCTION 
The concept of gene therapy, which involves introduction of DNA (or RNA) in the cell to 
cure or prevent diseases associated with defective gene expression, has opened up endless 
possibilities in the fields of bioengineering and genetics. Altering the genes by activating, 
silencing, introducing or knocking out, has opened the door to finding a cure for many 
diseases1. When the genes are transported to the nucleus of the cells, there is a possibility 
of the genes undergoing degradation because of presence of various degrading acids and 
enzymes present in the cells2. It becomes essential to incorporate the gene to be delivered 
in a proper gene delivery vehicle which protects it from this environment and delivers it 
to the nucleus. Viral vectors and synthetic vectors are major gene delivery carriers used 
today. Despite having high efficiency, viral vectors have a risk of reversion during 
replication of live viruses or even mutation to a more pathogenic state3. Non-viral 
vectors, however, have a disadvantage of low efficiency. To overcome the drawbacks of 
viral and synthetic vectors, the concept of a hybrid vector has been proposed. The vector 
is composed of a synthetic material and a virus-like particle (VLP). The hybrid vector 
carries the gene to be delivered but lacks the envelope protein which is essential for 
recognizing and binding a specific cell receptor and mediating entry into the cell. The
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synthetic part of the vector is composed of a polymer which fulfils the function of the 
envelope protein. 
The hybrid vector, however, has low efficiency compared to the viral vectors used in 
gene delivery. We hypothesize that the presence of proteins during the formation of the 
hybrid vector complex has a negative effect on the transduction efficiency of the hybrid 
vector. To improve the efficiency of the hybrid vector, we intend to purify the VLPs from 
these proteins and form the hybrid vector using purified VLPs. 
1.2 LITERATURE REVIEW 
1.2.1 Viral Vectors 
Most of the gene performed currently uses viral vectors. Retrovirus, adenovirus and 
adeno-associated virus are the major viral vectors used for gene delivery. One of the 
major advantages of using viral vectors is the extremely high efficiency of these viruses 
in delivery of genes to the target cells.  
Using viral vectors has not been without consequences. In a major setback to the use of 
viral vectors, a patient died after being administered with adenoviral vector for the 
treatment of partial deficiency of ornithine transcarbamylase4. The death was attributed to 
the acute inflammatory response to the adenoviral vector. 
Another major setback to the use of viral vectors occurred when children suffering from 
Severe Combined Immunodeficiency Disease (SCID) were treated with a gene-carrying 
retrovirus and developed leukemia. The retrovirus inserted the therapeutic gene and its 
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promoter near an oncogene of eleven patients. Three of the patients developed leukemia 
which led to a complete halt of viral gene therapy trials on human beings5. 
1.2.2 Synthetic Vectors 
Synthetic vectors include carrier vehicles like polyplexes6, micelles composed of block 
copolymers like poly(ethylene glycol)-block-polycations7, lipopolyplexes and 
lipoplexes8, matrix-degrading metalloproteinases9 and lipids. The use of copolymers for 
non-viral delivery of DNA was studied by d’Ayala et al10. In their study, the researchers 
synthesized a copolymer of polyethylenimine (PEI) and poly (Ε-caprolactum). This 
copolymer was used to form a complex with DNA and the complex used to transfect on 
human cervix epithelial carcinoma (HeLa) cells. They observed that though PEI by itself 
is cytotoxic, use of a PEI-based copolymer was less cytotoxic and helped to improve 
gene delivery. They also proved that they could have better control on gene delivery by 
controlling particle size and surface charge by modifying experimental condition and 
conditions at which the polymers were made. Despite the advantage of being relatively 
less toxic and less immunogenic, synthetic vectors have a drawback of low efficiency 
compared to viral vectors11. 
1.2.3 Hybrid Vectors 
Hybrid Vectors are composed of viral and non-viral (i.e. synthetic) components. The viral 
part performs the functions of intracellular trafficking, nuclear import and gene 
integration while the synthetic part does the function of viral envelope and facilitates 
endocytosis and endosomal escape. 
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Han et al tried to improve the transduction efficiency of recombinant adenovirus with a 
new synthetic polymer based on PEI12. They synthesized a copolymer of PEI with 
diethylene glycol (DEG). Adenoviruses need a coxsackie adenoviral receptor (CAR) 
receptor on the surface of the cell to undergo endocytosis. Complexes containing 
different ratios of polymer and adenovirus were formed and infected on Lewis Lung 
carcinoma (LLC), MDCK and A549 cell lines. The MDCK cell line is deficient. 
Enhancement in gene transfer efficiency was observed on native CAR positive target 
cells. In presence of copolymer, the complex also was able to infect the CAR negative 
cells. The study showed the ability of adenovirus to overcome intracellular barriers and 
the high efficiency of copolymer to endosomal escape were major factors which helped 
in improving the efficiency of the vector. Thus the combination of viral and non-viral 
vectors, which created a hybrid vector, was found to be effective in combining the 
advantages of both the vectors. 
Another approach for producing a hybrid vector is the use of  viral component called 
virus-like particles. VLPs consist of proteins that form the outer shell and the surface 
protein of the virus, without the RNA required for replication. These particles resemble 
the virus from which they are derived but lack the envelope protein. This makes the VLPs 
non-infectious. To make these non-infectious VLPs infectious, we add synthetic 
component, either lipid or polymer. 
Friedmann et al showed that non-infectious VLPs produced from Moloney murine 
leukemia virus (MoMLV) packaging cells can be made infectious by addition of 
lipofectin reagents13. The VLPs produced from MoMLV lack the viral envelope protein 
necessary infection. The envelope protein performs two important functions, recognition 
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of receptor for specific binding of the virus to a cell and fusion, which permits the release 
of uncoated virus and the viral RNA from the endosome into the cytoplasm. To make the 
non-infectious VLPs infectious, the lipofectin was added to the VLP solution. These 
VLPs and lipofectin were incubated and then added to target cells which were 
transfected. As controls, virus pseudotyped with vesicular stomatitis virus G protein 
(VSV-G) and VLPs without addition of lipofectin, were used to infect target cells. 
Reporter gene expression from the infection of lipofectin VLPs was compared with that 
from VSV-G pseudotyped viruses. VLPs without lipofectin did not show any gene 
expression. While the VLPs with lipofectin showed high gene expression. 
Ramsey et al formed hybrid vector complexes from retrovirus VLPs, derived from the 
Moloney murine leukemia virus (MoMLV-VLP), and either poly-L-lysine (PLL) or PEI 
and studied their transduction on HEK-293 cells14. MLV-VLPs were produced from the 
GP-293 Luc producer cell line which expresses the MLV gag-pol genes which assemble 
and form the MLV-VLPs. These VLPs bud from the producer cells. The supernatant 
containing VLPs was collected and PEI and PLL were added to the supernatant. 
Complexes were formed with different molecular weights of PEI and PLL and at 
different ratios of polymer/VLPs. Both PEI and PLL complexed VLPs showed good 
transduction. They studied the particle size with dynamic light scattering and particle 
morphology using transmission electron microscopy (TEM). The particle size was 
observed to be approximately 1,000 nm. Infection assay showed that the VLP/polymer 
complex was integrated in the cells. The large sized particles underwent successful 
transduction. This was due to the fact that large size would result in increased contact 
between complex and target cells. TEM micrographs showed particle morphology 
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showed a complex containing VLPs surrounding polymer aggregate. This morphology 
was hypothesized due to the presence of serum proteins in the VLP supernatant. The 
serum proteins were observed to take part in the complex formation and hence the size of 
complex was large. 
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CHAPTER II 
 
PURIFICATION OF VIRUS-LIKE PARTICLES FROM SERUM AND 
CELLULAR PROTEINS 
2.1 INTRODUCTION 
The relatively low hybrid vector efficiency observed by Ramsey et al may be due to the 
presence of serum and cellular proteins during the formation of complex between VLPs 
and polymer14. The VLPs were collected in supernatant containing serum and cellular 
proteins and PEI was added to this supernatant to form complexes. Cationic PEI is 
expected to form electrostatic complex with positively charges VLPs and proteins. The 
presence of serum and cellular proteins was also supposed to influence the morphology 
of complex formation. The complex was observed to be large in size and also showed a 
mixture of VLPs surrounding a mass of proteins and PEI. We decided to purify the VLPs 
from the serum and cellular proteins and then form complexes using purified VLPs and 
PEI and study their transduction. We decided to adopt and modify a purification strategy 
that would enable us to separate the proteins from VLPs. In absence of proteins, we 
expect a small sized complex to be formed which we expect to improve the transduction 
efficiency. 
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2.2 PURIFICATION STRATEGY  
2.2.1 Literature Survey 
A study of purification methods has shown that different techniques like cesium chloride 
ultracentrifugation, heparin affinity chromatography, size exclusion chromatography  and 
high performance liquid chromatography (HPLC) have been used for purifying viruses15. 
Transfiguracion et al, in their efforts to separate VSV-G virus from serum proteins, used 
the technique of HPLC. 
Edelstein et al used sucrose density gradient centrifugation to separate Ross River Virus 
and Barmah Forest Virus from proteins16.  Although the titers obtained for both type of 
viruses were quite high, this method has a drawback in that it cannot be used for large 
scale purification. Also, the infectivity of the recovered particles depends on the 
susceptibility of the particular pseudotyped retroviral vectors to hydrodynamic shear. 
Additionally, cellular debris, host nucleic acid and serum proteins that co-purify with the 
virus need to be removed in subsequent steps. 
Segura et al exploited heparin affinity chromatography to purify retroviral vectors from 
proteins17. They subjected the supernatant containing viral particles and proteins to ultra-
centrifugation, and the concentrated virus was added to a heparin affinity 
chromatography column. The viral particles were washed and then eluted using a NaCl 
gradient buffer. Despite obtaining high titers of viral vectors, the cost prohibits the use of 
this technique on large scale. 
 
9 
 
2.2.2 Purification Strategy 
The purification system we chose to purify the VLPs was adopted from Transfiguracion 
et al, who used the approach to purify VSV-G virus18. The process involves 
concentrating virus, digesting cellular RNA and DNA and separating virus from the 
supernatant proteins using size exclusion chromatography. 
VLPs are known to have an average size of 135-150 nm which was confirmed from 
DLS19. The proteins present in the medium have an average size of less than 10 nm. The 
proteins tend to agglomerate and form protein-protein complexes which had an average 
size of 40 nm (Figure 2.1). Thus the VLP supernatant was found to be comprised of 
particles with three different size categories: VLPs, 135 – 150 nm; proteins, 4 – 8 nm; 
protein agglomerates, 40 – 50 nm. 
 
Figure 2.1: DLS data showing size distribution of FBS in DMEM (A) and FBS and VLPs 
in DMEM (B) 
This size difference between VLPs and proteins was used to purify VLPs from proteins. 
Figure 2.2 gives an overview of our purification strategy. The purification process first 
involved concentrating the VLPs using an ultrafiltration cell with a polyvinylidene 
fluoride (PVDF) membrane having a MWCO of 300,000. This was followed by digestion 
of DNA and RNA using Benzonase nuclease. The last step used size exclusion chroma-g 
 Figure
tography, which separates molecules based on size,
small molecules are eluted 
size exclusion chromatography column. 
purification as described. The volume of VLP supernatant and the amount of infective 
VLPs change with each step of purification. The process also changes the concentration 
of proteins relative to the VLPs. As a result there are a number of
must be accounted for at the each step of purification. As such, we standardized our 
purification system to account for these factors using VSV
naturally infective and does
affect the infectivity of VSV
purification process and the percent recovery 
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 2.2: Brief Description of Purification Process 
 large molecules are eluted first and 
last. Tris-EDTA-NaCl (TEN) buffer is used for elution from 
These VLPs are subjected to different steps 
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-G virus. The VSV
 not require PEI. As such, the presence of prot
-G virus. The VSV-G virus was subjected to the same 
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ing that 
-G virus is 
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Figure 2.3: Purification of VSV-G virus (Avg. of three readings. P-values: 0.0077, 0.41, 
0.808) 
The percent recovery accounted for loss of virus and loss of activity (Figure 2.3). 
2.3 RESULTS AND DISCUSSION 
We initially identified SEC fractions containing VLPs and proteins. Both VLPs and 
proteins show high absorbance at 280 nm. We observed two sets of fractions showing 
high absorbance (Figure 2.4 A). To validate that the fractions eluted first contain VLPs, 
we performed an infection using all 30 fractions (Figure 2.4 B). The first few set of 
fractions showing high absorbance was found to give high values for infection. The 
second set of fractions showing high absorbance did not show any infection results which 
validated the fact that VLPs were eluted in the earlier fractions. 
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Figure 2.4: Absorbance (A) and infection (B) analysis of fractions obtained from size 
exclusion chromatography column (Avg. of 3 readings for absorbance, single reading for 
infection) 
The protein concentration was quantified at each step of the purification process using a 
BCA assay. The supernatant was diluted to the concentration of unpurified VLPs. The 
protein content in unpurified VLP supernatant was 2.95 µg/µl. The protein concentration 
calculated in the final purified VLPs was below the lower limit of the BCA assay kit 
(< 0.02 µg/µl) (Table 2.1).  
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Table 2.1: Protein concentration after each step of purification 
Type of VLPs Supernatant Protein Concentration (µg/ µl) 
Unpurified VLPs 2.95 
Stirred Cell Purified VLPs 22.01 
Benzonase Digested VLPs 14.56 
Size Exclusion Chromatography VLPs < 0.02 
 
To further demonstrate that the purification strategy separated VLPs and proteins, we 
carried out dynamic light scattering analysis of the purified supernatant and unpurified 
VLP supernatant (Figure 2.5). Based on the results the unpurified VLP supernatant 
contain particles with average diameters of 4 nm, 45 nm and 150 nm. These peaks 
correspond to proteins, protein agglomerates and VLPs. The peaks at 4 nm and 45 nm 
were absent in the purified VLP supernatant.  
 
Figure 2.5: DLS data showing unpurified (A) and purified (B) VLP supernatant 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis was 
carried out on samples collected at different stages of purification. The SDS-PAGE 
results indicate the presence of proteins and VLPs in the unpurified, ultrafiltered and 
benzonase digested samples. The concentration of VLPs in the final purified sample, 
however, was too low to be detected (Figure 2.6 A). In order to overcome this difficulty, 
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we used western blot analysis to detect purified VLPs. Rat monoclonal antibody for p10 
capsid protein and horse-radish peroxidase conjugated anti-rat IgG1 secondary antibodies 
were used. Detection of the labeled bands was carried out using a chromogenic detector 
and 3,3’,5,5’ –tetramethylbenzidine (TMB) substrate (Figure 2.6 B). 
 
Figure 2.6: SDS-PAGE (A) and Western Blot (B) analysis of VLPs at different stages of 
purification 
We used TEM to study the morphology of complexes formed using PEI and either 
unpurified or purified VLPs. Complexes were formed using both purified and unpurified 
VLPs and PEI and these complexes were fixed on a carbon-nickel grid. The grid was 
stained using phosphotungstic acid (PTA) and micrographs were obtained. The TEM 
micrographs for both purified and unpurified VLPs showed different morphology. For the 
complex formed from unpurified VLPs and PEI, a huge cluster of VLPs was observed. 
The cluster also contained some PEI and proteins. However, the cluster showed 
 morphology of PEI and proteins was surrounded by VLPs (Figure 2.7 A). In case of 
complex formed from purified VLPs and PEI, the morphology was different. It showed a 
single VLP particle surrounded by
the formation of agglomerates and as such smaller complexes were formed.
Figure 2.7: TEM micrographs showing complexes formed using
PEI (A) and purified VLPs and PEI
This finding is supported by the DLS data for complex
unpurified or purified VLPs 
complex size of 2300 nm. While the complex formed from purified VLP
gives a complex size 650 nm. This small complex size is due to absence of proteins in the 
complex.  
After each step of purification, the concentration of VLPs is changes. VLPs also undergo 
degeneration as they undergo the purification process. To c
15 
 PEI (Figure 2.7 B). The absence of proteins prevented 
 unpurified VLPs
 (B) (size bar is 100 nm)
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ompensate for above factors,
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Figure 2.8: DLS data showing complex formation using unpurified (A) and purified (B) 
VLPs with PEI 
we used the percent recovery of the VSV-G pseudotyped virus to adjust the volume of 
VLPs used for infection after each step of purification. Based on the VSV-G data, the 
amount of infective VLPs after each step of purification was normalized to that of 
unpurified VLPs. However, there was uncertainty in measuring the percent recovery of 
VSV-G virus after each step of purification. Hence, the overall recovery of VSV-G virus 
was calculated, which was 65 %. This percent recovery was used for normalizing 
concentration of VLPs after each step of purification. 
After normalizing the concentration of VLPs obtained at each step of purification, we 
formed complexes using VLPs and PEI. These complexes were incubated for two hours 
and then transfected on HEK-293 cells seeded at 1 × 106 cells/well in a six-well plate. 
After 48 hours, the HEK-293 cells were lysed and luciferase assay was performed to 
determine the amount of infection (Figure 2.9). Graph shows that after each step of 
purification, the transduction efficiency of VLPs goes on reducing. The transduction 
efficiency of final purified VLPs is less as compared to the transduction efficiency of 
unpurified VLPs. 
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Figure 2.9: Infectivity of VLPs after each step of purification (Average of 3 readings, P-
values: 0.66, 0.12, 0.069) 
BCA assay showed us that the protein concentration is changing after each step of 
purification (Figure 2.10). If we compare the protein concentration and transduction 
efficiency of VLPs after each step of purification, we find that after ultrafiltration, the 
protein concentration is increased. However, the transduction efficiency is reduced. 
Conversely, the concentration of proteins in the size exclusion chromatography purified 
VLPs is negligible. The transduction efficiency is still reduced. To justify this effect, we 
compared data obtained from BCA assay, infection analysis and DLS analysis. 
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Figure 2.10: Amount of Supernatant Proteins per amount of VLPs after each step of 
purification 
The DLS data showed that the size of complex formed from purified VLPs and PEI was 
smaller than the size of complex formed from unpurified VLPs and PEI. However, the 
complex of purified VLP-PEI was less infective as compared to complex formed from 
unpurified VLP-PEI. The size of complex formed could be one of the factors that could 
affect the transduction of VLP-PEI complex on cells. Landazuri et al studied the factors 
affecting the transduction of retrovirus-polymer complex. In their study, they added 
oppositely charged polymers such as polybrene and chondroitin sulfate C (CSC) to 
retrovirus stocks and studied their transfection on cells. They observed that the 
complexes formed from polymer and viruses tend to sediment rapidly on the cells as 
compared to adding viruses alone. With increase in concentration of polymer, the size of 
complexes increased and so did the infection which was attributed to increase in the rate 
of sedimentation of the complexes on the cells20.  
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The same scenario may apply to our hybrid vector. In place of the negatively charged 
polymer, however, we have negatively charged proteins. The negatively charged proteins 
help in formation of large size of complex which rapidly sediments on the cells. Absence 
of proteins, leads to formation of small sized complex which does not settle rapidly on 
the cells. Presence of too low amounts of proteins could lead to formation of smaller 
complexes between VLPs and PEI and this could lead to diffusion of complex before it 
reaches the cell surface. Presence proteins help in formation of large complexes which 
tend to sediment rapidly on the cell surface and thus improve the transduction efficiency 
of the complex. 
2.4 CONCLUSION 
Our findings show that the serum and cellular proteins present during a complex 
formation have a significant impact on the transduction efficiency of the resulting 
complex. The infectivity of the final purified VLPs is less than the infectivity of 
unpurified VLPs. An excess of proteins also hinders the transduction efficiency of the 
complex. 
We concluded that there is some amount of proteins required for the formation of an 
infective VLP-PEI complex. 
2.5 MATERIALS AND METHODS 
Cell Lines: Human embryonic kidney (HEK) cells, HEK-293, and a murine leukemia 
virus packaging cell line, GP-293Luc, were used for our experiments. HEK-293 cells 
were purchased from American Type Culture Collection, Manassas, VA. GP-293Luc 
cells were purchased from Clontech Laboratories Inc., Mountain View, CA. Both cell 
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lines were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10 
% fetal bovine serum and cultured at 37 oC in 5 % CO2.  
Virus and Virus-Like Particles: Envelope-free MLV-VLPs with a luc reporter gene were 
produced from the GP-293Luc cell line. GP-293Luc cells were seeded at 1.5 × 106 in 12 
ml of medium on a 10 cm dish. The cells were cultured for three days before the 
supernatant was collected and filtered through a 0.45 µm polyethersulfone syringe filter. 
Filtered virus-like particles were used immediately.  
Vesicular Stomatitis Virus – Glycoprotein (VSV-G) pseudotyped viruses were produced 
by transfecting the GP-293 Luc cells with the plasmid pVSV-G. The cells were seeded in 
a 10 cm dish 18 – 24 hours prior to transfection so as to be ~90 % confluent at the time of 
transfection. The cells were transfected with 24 µg of envelope plasmid (pVSV-G) using 
Lipofectamine 2000 and following the protocol supplied with the transfection reagent. 
The transfection medium was replaced after 6 hours. Viruses were collected 48 hours 
later and filtered through 0.45 µm polyethersulfone syringe filter. 
Polymer: Polyethylenimine was purchased through Sigma-Aldrich, St. Louis, MO. Stock 
solutions of the polymer were prepared in ultrapure water at a concentration of 10 mg/ml 
and stored at 4 oC.  
Hybrid Vector Formation: Polymer/VLP complexes were formed through drop-wise 
addition of stock polymer solution to VLP supernatant while vortexing. Polymer from the 
stock solution was added to VLPs in a 1.5 ml ultracentrifuge tube and vortexed. The 
polymer/VLP solution was incubated at room temperature for two hours before infecting 
the cells. 
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Cell Transduction: HEK-293 target cells were seeded in 6-well plates 18 – 24 hours  
before transduction at a seeding density of 1 × 106 cells/well. Immediately before 
addition of hybrid vector complexes the cell growth medium was replaced with serum-
free DMEM. Hybrid vector complexes were then added to each well and incubated at 37 
oC. After four hours, the medium was replaced with serum medium. 
Gene Expression Assay: Cells infected with polymer/VLP complexes were assayed after 
48 hours after the addition of the vector. For detection of luciferase protein the growth 
medium was aspirated and 200 µl of cell culture lysis reagent (CCLR), Promega Inc., 
Madison, WI, was added to the cells. The cells were lysed at room temperature for 10 
minutes followed by a 5 minutes freeze-thaw cycle at -80 oC. Luciferase activity for 20 µl 
of the cell lysate was measured using Promega’s Luciferase Assay System and a Lumat 
LB9507 luminometer, EG&G Berthold, Bundoora, Australia. 
Protein Assay: Protein analysis was carried out using the BicinChoninic Acid (BCA) 
assay from Pierce, Rockford, IL. The microplate procedure for 96-well plate was 
followed. Working Reagent from BCA reagent A and BCA reagent B was prepared. The 
sample addition and working reagent addition was done as per the manufacturers’ 
protocol. Plate reader from Packard Biosciences, Illinois, was used to take absorbance 
readings at 560 nm. 
Transmission Electron Microscopy: VLP and VLP/polymer complexes formed form 
unpurified and purified VLPs were fixed using 50 µl of Karnovsky’s fixative to 100 µl of 
sample. A carbon formvar grid was held in a tweezers and a few drops of sample were 
added to the grid in such a way that small amount of sample was allowed to overflow the 
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grid. The grid was exposed to the sample for three minutes. The grid was then rinsed with 
PBS. Two drops of Uranyl Acetate (UA) stain were added dropwise on the grid in such a 
way that the stain replaced the excess of sample on the grid. The grid was stained for two 
minutes. The excess UA was wicked off using filter paper. The grid was dried for 10 
minutes before viewing using JEOL JEM-2100 Scanning Transmission Electron 
Microscope System. 
Ultrafiltration: A stirred cell ultrafiltration unit, Millipore Inc., Bedford, MA, was used 
for concentrating the VLPs. An ultra-filtration membrane, Millipore Inc., Bedford, MA, 
with a molecular weight cut-off (MWCO) of 300,000 was used. A steady operating 
pressure of 45 PSI was used to pressurize the ultrafiltration chamber. The stirrer speed 
was maintained at 60 rpm. 
Benzonase Digestion: Benzonase nuclease was obtained from Novagen. Concentrated 
solution with an activity of 10,000 units/µl was diluted down to an activity of 250 
units/µl using the Tris-EDTA-NaCl (TEN) buffer. The diluted solution was stored at 
-20 oC. 
Size Exclusion Chromatography: Protein A sepharose CL-4B, Amersham Biosciences, 
Piscataway, NJ, was packed in a glass column XK16/40 (Fisher Scientific). The gel was 
packed using a continuous flow of ethanol and then further flushed with (TEN) buffer 
before running the sample. After running each cycle, the column is flushed with 50 ml 
1N NaOH (as per manufacturer’s instructions) and then flushed with 150 ml of TEN 
buffer to clean the column of NaOH. 
23 
 
Absorbance Reader: The fraction analysis was carried out using Cary UV-Visible 
Spectrophotometer. The analysis was carried out using an un-built filter measuring for a 
wavelength of 280 nm. 
Sodium Dodecyl Sulfate – Polyacrylamide Gel Electrophoresis (SDS-PAGE): The SDS-
PAGE analysis was carried out using XCell II Blot Module, Invitrogen, Carlsbad, CA. 
The gels used were 4 – 20 % gradient gels obtained from Pierce Biotechnology and 
Electrophoresis, Rockford, IL. Tris-HEPES-SDS running buffer was prepared from 100 
mM Tris, 100 mM HEPES and 3 mM SDS. One liter of running buffer is sufficient to run 
2 gels. Sample buffer was obtained from Expedeon, San Deigo,CA. Sample buffer was 
diluted to 1X concentration using DI water. Sample and sample buffer were mixed in a 
ratio of 4:1 and the mixture was boiled for 5 minutes at 100 oC. A volume of 5 – 10 µl of 
sample was added to each well of the gel. Protein ladder was obtained from Expedeon, 
San Deigo, CA. The gels were run at 125 volts for 45 minutes as per manufacturers’ 
instructions. 
For detection, we used Pro Sieve Blue Protein Staining Solution obtained from Lonza, 
Rockland, ME. Microwave instructions mentioned on the bottle of the staining solution 
were followed. 
Western Blot Analysis: Producer cells for rat IgG1 monoclonal antibody were obtained 
from American Type Culture Collection, Manassa, VA. The cells were grown in RPMI 
1640 medium supplemented with 10 % fetal bovine serum and 0.05 mM 
2-β-mercaptoethanol. Antibodies were secreted into the medium and the medium 
collected off the cells after 96 hours. The antibodies were purified using Montage 
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Antibody Purification Prosep-G Kit, Millipore Corporation, Billerica, MA, following the 
manufacturer’s protocol. 
Horseradish Peroxidase Conjugated anti-rat secondary antibody was obtained from 
Jackson Immunoresearch, West Groove, PA. The antibody was diluted to a concentration 
of 1:50,000 in DI water per the manufacturer’s instructions. 
Immobilon transfer membranes were obtained from Millipore Corporation, Bedford, MA. 
Transfer buffer was made from 125 mM Tris and 960 mM glycine. Wash buffer was 
made from Tween20 (Fisher Scientific, NJ) in PBS. Stock solution was made of 25 % 
Tween20. Wash buffer was made by adding 8 ml from stock solution to 2,000 ml of PBS.  
SDS-PAGE analysis of samples was carried out. The samples were transferred from the 
acrylamide gel to a PVDF membrane using the Transblot semi-dry transfer cell at 0.45 
volts for 37 minutes. The PVDF membrane was washed with wash buffer and was 
exposed to primary antibody with continuous stirring for two hours. The membrane was 
blocked using a blocking reagent from Li-Cor. A preset program on the Li-Cor blot 
washer was used to perform two cycles involving exposure to secondary antibody 
followed by washing.  The membrane was subsequently exposed to  
3,3’,5,5’-tetramethylbenzidine (TMB) substrate and colored bands appeared. When the 
required band intensity was achieved, the membrane was washed with DI water for 5 
minutes. 
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CHAPTER III 
 
ADDITION OF PROTEINS TO IMPROVE TRANSDUCTION EFFICIENCY 
3.1 INTRODUCTION 
The reduced transduction efficiency of the purified VLPs led to further questions about 
the role of proteins on complex formation and transduction efficiency. It was also noted 
that complexes formed from purified VLPs and PEI were much smaller in size compared 
to those formed from unpurified VLPs and PEI. To study these effects, we added proteins 
to the purified VLPs and formed complexes. A comparison was performed between 
complexes formed using unpurified VLPs and purified VLPs and purified VLPs with 
increasing amounts of protein. 
3.2 ADDITION OF PROTEINS 
We added both cellular and serum proteins to purified VLPs in order to make the 
conditions similar to the ones in which VLPs are present before purification. It is 
however difficult to quantify the exact amount of serum and cellular proteins present in 
the supernatant. We approximated the conditions by forming a stock solution containing 
nearly 90 % serum proteins and 10 % cellular proteins by weight. Fetal bovine serum was 
used as a source of serum proteins. The protein concentration in FBS was found to be 
57 µg/µl.  HEK-293 cell supernatant was collected and concentration of proteins in the
26 
 
supernatant was calculated to be 5.3 µg/µl. From the stock solution, we added different 
amounts of proteins to the purified VLPs. The purified VLPs were diluted to bring the 
concentration same as that of unpurified VLPs using TEN buffer and proteins from the 
stock solution, the dilution factor for which was based on the percent recovery of the 
VSV-G pseudotyped VLPs as described in chapter 2. The amount of proteins and TEN 
buffer used in the experiment is described below. 
3.2.1 Sample Calculations 
The concentration of proteins in the final purified VLP solution is considered negligible 
(< 0.02 µg/µl). Therefore, the amount of serum and cellular proteins added can be used in 
calculating the final concentration of proteins in the sample (Table 3.2). A stock protein 
solution was used to prepare the protein/VLP samples. The stock solution was prepared 
from equal volumes of serum proteins (57 µg/µl) and cell culture supernatant (5.3 µg/µl) 
to give a stock protein concentration of 31.15 µg/µl. 
Different samples containing different volumes of stock protein solution were prepared. 
The amount of TEN buffer added to the final solution was adjusted so that the final 
volume is 500 µl after adding the protein stock solution. The concentration of VLPs in 
the solution after forming the above mentioned solution is same as concentration of VLPs 
in the unpurified sample. The concentration of proteins in the final solution was 
calculated for different volumes of stock solution using a simple material balance 
equation (Equation i) where C1 is the concentration of proteins in the stock solution and 
V1 is the volume of proteins in the stock solution. The term C2 is the concentration of 
proteins in the final solution and V2 be the volume of final solution. 
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                                                           C1V1 = C2V2                                                     Equation i)               
For example, our first sample combines 166 µl VLPs, 332 µl of TEN buffer and 2 µl of 
the stock protein solution. Using material balance shown in equation i) the final protein 
concentration is 
31.15 µg/µl × 2 µl = C2 × 500 µl 
C2 = 0.12 µg/µl 
Similarly, protein concentrations for different amounts of stock solution added to the 
final solution were calculated as shown in the table below. 
Table 3.1: Calculation of protein concentration added to the purified VLPs to form 
complex. 
Amount of VLPs 
(µl) 
Amount of TEN 
buffer (µl) 
Amount of Protein 
from stock 
solution (µl) 
Concentration of 
protein in final 
solution (µg/µl) 
166 334 0 0 
166 332 2 0.12 
166 324 10 0.62 
166 314 20 1.24 
166 304 30 1.86 
166 294 40 2.50 
166 284 50 3.11 
166 274 60 3.73 
 
3.3 RESULTS AND DISCUSSIONS 
Adding proteins before polymer/VLP complex formation had an effect on the 
transduction efficiency. The protein concentration in unpurified VLP solution was 
2.95 µg/µl. The protein concentration in purified VLPs was below the limit of the BCA 
assay (< 0.02 µg/µl). As proteins were added initially, the transduction efficiency 
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decreased. For a concentration of 0.62 µg/µl, however, the transduction efficiency 
increased substantially to a level (Figure 3.1) greater than that of unpurified VLPs (i.e., 
when the VLPs contained serum and cellular proteins in unknown proportion). As the 
protein concentration was increased further however the transduction efficiency 
decreased gradually until the concentration exceeded 2.5 µg/µl. The transduction 
efficiency did not change to a large extent. As the protein concentration increased above 
3.1 µg/µl the hybrid vector transduction efficiency essentially reached zero. At a protein 
concentration 3.7 µg/µl, no transduction of complex was observed. 
 
Figure 3.1: Effect on transduction efficiency of purified VLPs after adding proteins 
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Figure 3.2: DLS data showing Unpurified VLP-PEI complex (A), Purified VLP-PEI 
complex (B), Purified VLPs + 0.12µg/µl proteins – PEI complex (C), Purified VLPs + 
0.62 µg/µl proteins – PEI complex (D), Purified VLPs + 1.24 µg/µl proteins – PEI 
complex (E), Purified VLPs + 1.86 µg/µl proteins – PEI complex (F) 
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Figure 3.2 - continued: DLS data showing Purified VLPs + 2.5 µg/µl proteins – PEI 
complex (G), Purified VLPs + 3.11 µg/µl proteins + VLPs (H), Purified VLPs + 3.73 
µg/µl proteins – PEI complex (I) 
The DLS was used to analyze size of complexes after adding proteins to purified VLPs 
and PEI. The data shows that increasing the protein concentration increases the size of 
the complex. The size of the complex formed from purified VLPs with 0.62 µg/µl of 
protein is same as that formed from unpurified VLPs. The transduction efficiency of the 
complexes formed from purified VLPs with 0.62 µg/µl of proteins and unpurified VLPs 
was also found to be same. As we go on adding more proteins however the size of 
complex goes is reduced. For a concentration of 3.11 µg/µl and 3.73 µg/µl of proteins, 
very little complex is formed. We see a large number of particles formed which have an 
average size of 50 nm. These particles could be the protein-PEI complexes which are not 
infective.  
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Table 3.2: Size analysis and transduction efficiency of complexes formed with different 
amount of proteins 
Type of Complex Size (nm) RLUs 
Unpurified VLP-PEI Complex 2300 6.5 × 106 
Purified VLP-PEI Complex 650 4.8 × 106 
Purified VLP-PEI Complex + 0.12 µg/µl proteins 1400 4.0 × 106 
Purified VLP-PEI Complex + 0.62 µg/µl proteins 2200 7.4 × 106 
Purified VLP-PEI Complex + 1.24 µg/µl proteins 2000 5.5 × 106 
Purified VLP-PEI Complex + 1.86 µg/µl proteins 1650 4.8 × 106 
Purified VLP-PEI Complex + 2.5 µg/µl proteins 1700 4.4 × 106 
Purified VLP-PEI Complex + 3.11 µg/µl proteins 160 0.8 × 106 
Purified VLP-PEI Complex + 3.73 µg/µl proteins 200 0 
 
Another factor that may be contributing to reduced infectivity is charge difference 
generated in the complex due to proteins. In their study, Landazuri et al added a cationic 
and anionic polymer to retrovirus and studied their transduction in comparison with 
normal retrovirus. Apart from the fact that size plays an important role in rapid 
sedimentation of virus-polymer complex on the surface of the cells, they concluded that 
the presence of negatively charged polymer helps in protecting the cells from what would 
otherwise be cytotoxic effect of the cationic polymer. They observed that when the dose 
of cationic polymer was higher than that of anionic polymer, it affected the transduction 
efficiency because of cytotoxic effect of excess of cationic polymer21. Extending the 
same theory to our PEI-VLP complex, when the complexes are formed from purified 
VLPs and PEI, we find that the transduction efficiency is reduced which could be due to 
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the presence of excess of cationic polymer. When we start adding proteins, the proteins 
start taking part in the complex formation. This leads to reduction of presence of excess 
of cationic polymer surrounding the cells and as such reduces the cytotoxic effect of the 
polymer. 
3.4 CONCLUSION 
VLPs require the presence of proteins to form infective complex with PEI. Presence of 
proteins increases the size of the complex which leads to faster sedimentation of the 
complex on the cells and may also decrease the cytotoxic effect of the cationic polymer. 
3.5 MATERIALS AND METHODS 
Cell Lines: Human embryonic kidney (HEK) cells, HEK-293, and a murine leukemia 
virus packaging cell line, GP-293Luc, were used for our experiments. HEK-293 cells 
were purchased from American Type Culture Collection, Manassa, VA. GP-293Luc cells 
were purchased from Clontech Laboratories Inc., Mountain View, CA. Both cell lines 
were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10 % 
fetal bovine serum and cultured at 37 oC in 5 % CO2.  
Virus and Virus-Like Particles: Envelope-free MLV-VLPs with a luc reporter gene were 
produced from the GP-293Luc cell line. GP-293Luc cells were seeded at 1.5 × 106 in 12 
ml of medium on a 10 cm dish. The cells were cultured for three days before the 
supernatant was collected and filtered through a 0.45 µm polyethersulfone syringe filter. 
Filtered virus-like particles were used immediately.  
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Vesicular Stomatitis Virus – Glycoprotein (VSV-G) pseudotyped viruses were produced 
by transfecting the GP-293 Luc cells with the plasmid pVSV-G. The cells were seeded in 
a 10 cm dish 18 – 24 hours prior to transfection so as to be ~90 % confluent at the time of 
transfection. The cells were transfected with 24 µg of envelope plasmid (pVSV-G) using 
Lipofectamine 2000 and following the protocol supplied with the transfection reagent. 
The transfection medium was replaced after 6 hours. Viruses were collected 48 hours 
later and filtered through 0.45 µm polyethersulfone syringe filter. 
Polymer: Polyethylenimine was purchased through Sigma-Aldrich, St. Louis, MO. Stock 
solutions of the polymer were prepared in ultrapure water at a concentration of 10 mg/ml 
and stored at 4 oC.  
Hybrid Vector Formation: Polymer/VLP complexes were formed through drop-wise 
addition of stock polymer solution to VLP supernatant while vortexing. Polymer from the 
stock solution was added to VLPs in a 1.5 ml ultracentrifuge tube and vortexed. The 
polymer/VLP solution was incubated at room temperature for two hours before infecting 
the cells. 
Cell Transduction: HEK-293 target cells were seeded in 6-well plates 18 – 24 hours 
before transduction at a seeding density of 1 × 106 cells/well. Immediately before 
addition of hybrid vector complexes the cell growth medium was replaced with serum-
free DMEM. Hybrid vector complexes were then added to each well and incubated at 
37 oC. After four hours, the medium was replaced with serum medium. 
Gene Expression Assay: Cells infected with polymer/VLP complexes were assayed after 
48 hours after the addition of the vector. For detection of luciferase protein the growth 
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medium was aspirated and 200 µl of cell culture lysis reagent (CCLR), Promega Inc., 
Madison, WI, was added to the cells. The cells were lysed at room temperature for 10 
minutes followed by a 5 minutes freeze-thaw cycle at -80 oC. Luciferase activity for 20 µl 
of the cell lysate was measured using Promega’s Luciferase Assay System and a Lumat 
LB9507 luminometer, EG&G Berthold, Bundoora, Australia. 
Protein Assay: Protein analysis was carried out using the BicinChoninic Acid (BCA) 
assay from Pierce, Rockford, IL. The microplate procedure for 96-well plate was 
followed. Working Reagent from BCA reagent A and BCA reagent B was prepared. The 
sample addition and working reagent addition was done as per the manufacturers’ 
protocol. Plate reader from Packard Biosciences, Illinois, was used to take absorbance 
readings at 560 nm. 
Ultrafiltration: A stirred cell ultrafiltration unit, Millipore Inc., Bedford, MA, was used 
for concentrating the VLPs. An ultra-filtration membrane, Millipore Inc., Bedford, MA, 
with a molecular weight cut-off (MWCO) of 300,000 Da was used. A steady operating 
pressure of 45 PSI was used to pressurize the ultrafiltration chamber. The stirrer speed 
was maintained at 60 rpm. 
Benzonase Digestion: Benzonase nuclease was obtained from Novagen. Concentrated 
solution with an activity of 10,000 units/µl was diluted down to an activity of 
250 units/µl using the TEN buffer. The diluted solution was stored at -20 oC. 
Size Exclusion Chromatography: Protein A sepharose CL-4B (Amersham Biosciences) 
was packed in a glass column XK16/40 (Fisher Scientific). The gel was packed using a 
continuous flow of ethanol and then further flushed with Tris-EDTA-NaCl (TEN) buffer 
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before running the sample. After running each cycle, the column is flushed with 50 ml 
1N NaOH (as per manufacturer’s instructions) and then flushed with 150 ml of TEN 
buffer to clean the column of NaOH. 
Absorbance Reader: The fraction analysis was carried out using Cary 50 UV-Visible 
Spectrophotometer. Absorbance was measured at a wavelength of 280 nm. 
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CHAPTER IV 
 
FUTURE WORK 
The unpurified VLPs contained unspecified amount of serum and cellular proteins. 
However, when we added back proteins, we added equivalent amount of serum and 
cellular proteins. Hence, it becomes necessary to analyze the effect of adding only serum 
proteins and only cellular proteins to the VLPs and as such their effect on complex 
formation and transduction. 
We formed complexes between VLPs and PEI. PEI is the most widely used polymer in 
gene therapy. However, toxicity has been a major issue in the use of PEI. Previous efforts 
have shown use of poly-L-lysine (PLL) and co-polymers for gene delivery. Using of PLL 
and co-polymers for delivery of purified VLPs would be an attractive alternative.
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Findings and Conclusions:  Our experiments showed that removal of proteins decreased 
the transduction efficiency of the hybrid vector. We also observed changes in the 
morphology of complex formed from purified VLPs and PEI compared to that 
formed from unpurified VLPs and PEI.  
 
We concluded that proteins have an impact on hybrid vector complex formation 
and transduction efficiency. Removal of proteins decreased the transduction 
efficiency of the hybrid vector and changes the morphology of the hybrid vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
